on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Interests in Avadel Pharmaceuticals
The Vanguard Group, Inc. has disclosed its interests and short positions in Avadel Pharmaceuticals plc. According to Form 8.3, filed under the Irish Takeover Panel rules, Vanguard holds 5,787,867 ordinary shares, representing a 5.94% interest in the company. This disclosure comes as of January 29, 2026.
The filing states no additional dealings beyond these equity interests, and no cash-settled or stock-settled derivatives have been reported. Furthermore, there are no indemnity or other agreements related to securities of Avadel Pharmaceuticals linked to this disclosure.
This transparency is part of the regulatory requirements under the Irish Takeover Panel Act of 1997, ensuring that significant shareholders disclose their positions for market integrity and investor awareness.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news